Cargando…

A protocol for a randomised, double-blind, placebo-controlled study of the effect of LIraglutide on left VEntricular function in chronic heart failure patients with and without type 2 diabetes (The LIVE Study)

INTRODUCTION: Heart failure is one of the most common cardiovascular complications of diabetes and the most disabling and deadly complication too. Many antidiabetic agents have been associated with increased morbidity and mortality in a subset of patients with chronic heart failure (CHF); thus, new...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jorsal, Anders, Wiggers, Henrik, Holmager, Pernille, Nilsson, Brian, Nielsen, Roni, Boesgaard, Trine Welløv, Kumme, Anja, Møller, Jacob Eifer, Videbæk, Lars, Kistorp, Caroline, Gustafsson, Ida, Tarnow, Lise, Flyvbjerg, Allan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2014
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4039804/ https://www.ncbi.nlm.nih.gov/pubmed/24844271 http://dx.doi.org/10.1136/bmjopen-2014-004885

Ejemplares similares

Galectin-3 and fibulin-1 in systolic heart failure - relation to glucose metabolism and left ventricular contractile reserve
por: Holmager, Pernille, et al.
Publicado: (2017)

Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF)
por: Jensen, Jesper, et al.
Publicado: (2019)

The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure: a randomized controlled trial (Empire HF Biomarker)
por: Omar, Massar, et al.
Publicado: (2022)

Efficacy and Safety of IDegLira in Participants with Type 2 Diabetes in India Uncontrolled on Oral Antidiabetic Drugs and Basal Insulin: Data from the DUAL Clinical Trial Program
por: Khunti, Kamlesh, et al.
Publicado: (2017)

Plasma Growth Differentiation Factor-15 Independently Predicts All-Cause and Cardiovascular Mortality As Well As Deterioration of Kidney Function in Type 1 Diabetic Patients With Nephropathy
por: Lajer, Maria, et al.
Publicado: (2010)

Effects of liraglutide on gallbladder emptying: A randomized, placebo‐controlled trial in adults with overweight or obesity
por: Nexøe‐Larsen, Christina C., et al.
Publicado: (2018)

Vitamin D, carotid intima–media thickness and bone structure in patients with type 2 diabetes
por: Winckler, Karoline, et al.
Publicado: (2015)

Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS
por: Frøssing, Signe, et al.
Publicado: (2017)

Liraglutide in polycystic ovary syndrome: a randomized trial, investigating effects on thrombogenic potential
por: Nylander, Malin, et al.
Publicado: (2017)

IDegLira Improves Both Fasting and Postprandial Glucose Control as Demonstrated Using Continuous Glucose Monitoring and a Standardized Meal Test
por: Holst, Jens J., et al.
Publicado: (2015)

Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes
por: Hansen, Christian Stevns, et al.
Publicado: (2019)

Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes—a protocol for a randomised, double-blind, placebo-controlled study: The Lira-1 study
por: Dejgaard, Thomas Fremming, et al.
Publicado: (2015)

Higher Plasma Levels of Advanced Glycation End Products Are Associated With Incident Cardiovascular Disease and All-Cause Mortality in Type 1 Diabetes: A 12-year follow-up study
por: Nin, Johanna W., et al.
Publicado: (2011)

Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
por: Nauck, Michael, et al.
Publicado: (2009)

End-systolic wall stress in aortic stenosis: comparing symptomatic and asymptomatic patients
por: Carter-Storch, Rasmus, et al.
Publicado: (2019)

SAT-097 Weight Loss With Liraglutide 3.0 Mg Versus Placebo For Individuals Who Adhere To The Trial Drug: A Secondary Analysis From SCALE IBT
por: Shaw Tronieri, Jena, et al.
Publicado: (2019)

SAT-099 Liraglutide 3.0 mg as an Adjunct to Intensive Behavior Therapy in Individuals with Obesity: SCALE IBT 56-Week Randomized, Double-Blind, Placebo-Controlled Trial
por: Wadden, Thomas, et al.
Publicado: (2019)

Effect of Acute Hyperglycemia on Left Ventricular Contractile Function in Diabetic Patients with and without Heart Failure: Two Randomized Cross-Over Studies
por: Nielsen, Roni, et al.
Publicado: (2013)

Higher Plasma Soluble Receptor for Advanced Glycation End Products (sRAGE) Levels Are Associated With Incident Cardiovascular Disease and All-Cause Mortality in Type 1 Diabetes: A 12-Year Follow-Up Study
por: Nin, Johanna W.M., et al.
Publicado: (2010)

Metformin versus placebo in combination with insulin analogues in patients with type 2 diabetes mellitus—the randomised, blinded Copenhagen Insulin and Metformin Therapy (CIMT) trial
por: Lundby-Christensen, Louise, et al.
Publicado: (2016)

Effects of Liraglutide on Left Ventricular Function: A Meta-Analysis of Randomized, Placebo-Controlled Trials
por: Zhong, Zhaoshuang, et al.
Publicado: (2021)

SAT-105 Weight Loss As Determined By Adherence To Reduced Caloric Diet, Increased Physical Activity, Liraglutide 3.0 Mg and Placebo: A Sub-analysis Of The SCALE IBT Trial
por: Shaw Tronieri, Jena, et al.
Publicado: (2019)

Variant near ADAMTS9 Known to Associate with Type 2 Diabetes Is Related to Insulin Resistance in Offspring of Type 2 Diabetes Patients—EUGENE2 Study
por: Boesgaard, Trine Welløv, et al.
Publicado: (2009)

Body mass index in chronic heart failure: association with biomarkers of neurohormonal activation, inflammation and endothelial dysfunction
por: Christensen, Heidi M, et al.
Publicado: (2013)

Association between left ventricular diastolic function and right ventricular function and morphology in asymptomatic aortic stenosis
por: Christensen, Nicolaj Lyhne, et al.
Publicado: (2019)

Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management
por: Kolotkin, R. L., et al.
Publicado: (2016)

Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial
por: Bizino, Maurice B., et al.
Publicado: (2019)

Liraglutide – Indian Experience
por: Anirban, Majumder, et al.
Publicado: (2018)

Liraglutide-Induced Hepatotoxicity
por: Maor, Yaakov, et al.
Publicado: (2021)

Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded, parallel intervention study
por: Idorn, Thomas, et al.
Publicado: (2013)

Correction to: Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial
por: Bizino, Maurice B., et al.
Publicado: (2019)

STATUS QUO 2020: what have we learned so far in temporary mechanical circulatory support? Use of Impella beyond the cathlab: open issues and clinical needs
por: Pappalardo, Federico, et al.
Publicado: (2021)

Variables associated with HbA1c and weight reductions when adding liraglutide to multiple daily insulin injections in persons with type 2 diabetes (MDI Liraglutide trial 3)
por: Dahlqvist, Sofia, et al.
Publicado: (2018)

Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials
por: Zhao, Xu, et al.
Publicado: (2019)

Circulating matrix metalloproteinases are associated with arterial stiffness in patients with type 1 diabetes: pooled analysis of three cohort studies
por: Peeters, Stijn A., et al.
Publicado: (2017)

Insulin Gene Mutations Resulting in Early-Onset Diabetes: Marked Differences in Clinical Presentation, Metabolic Status, and Pathogenic Effect Through Endoplasmic Reticulum Retention
por: Meur, Gargi, et al.
Publicado: (2010)

Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo‐controlled trial
por: Ahmann, A., et al.
Publicado: (2015)

Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study
por: Peeters, S. A., et al.
Publicado: (2017)

Biliary effects of liraglutide and sitagliptin, a 12‐week randomized placebo‐controlled trial in type 2 diabetes patients
por: Smits, Mark M., et al.
Publicado: (2016)

Cardiovascular outcomes in patients who experienced a myocardial infarction while treated with liraglutide versus placebo in the LEADER trial
por: Nauck, Michael A, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_oej5lgs1nvnr7mnus1mjl2hn6n